about
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation.Rational Clinical Experiment: Assessing Prior Probability and Its Impact on the Success of Phase II Clinical Trials.What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors.Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Update on management of midgut neuroendocrine tumors.Management of pancreatic neuroendocrine tumors.Resectable, borderline resectable, and locally advanced pancreatic cancer: what does it matter?A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.Clinical Trial Design in Neuroendocrine Tumors.Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors.[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors.Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.Future Directions in the Biology of Neuroendocrine Tumors.Is estrogen exposure a protective factor for pancreatic neuroendocrine tumours in female patients with multiple endocrine neoplasia syndrome type 1?Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors.Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database StudyIncidence and prognosis of carcinoid syndrome: hormones or tumour burden? - Authors' reply
P50
Q34017912-7BDAE1B0-3DB1-4294-9D79-52780AEBB2B7Q34156078-1762A1B5-D8CF-4E3B-999A-55CF02F73BCBQ36011161-E3E0BABB-52B7-4298-978F-03C0BAFDB87AQ36205323-3359FDDE-05D0-4170-AFFB-BE6953E25694Q36708349-6AC9E8B5-E953-488A-A2FD-FC18CAD5EB66Q37025143-D8EF4F5B-169F-48E1-8A79-405886BBD449Q37984981-C9A4D44A-511A-4E37-BC09-C011D80159DAQ38180310-2B89E3EA-55DB-4140-A0A9-A70C8B429417Q38262229-7CEC77B3-24ED-4151-BDD8-D7B94E01FC3BQ38650884-AFF6E698-1E9F-4040-83CE-706FE41EF047Q38690230-769AD975-7D02-403D-B472-7DDECEA20C74Q38690778-CBA134EB-ECA8-4ADE-BDFE-C9B865F0B076Q38694105-09ACC204-D24A-4B2E-ACB1-EC574672FACCQ38713088-458D99D9-5F70-4CF7-98BD-2455A5D85D17Q38753074-D716E278-D719-464C-B8F4-42C35161B64DQ38853921-A77BC7A5-C9C5-446B-9879-0F1D016D6567Q39168537-1A47CC84-19BB-4539-A8FB-63056B3A2A24Q53027231-04801F3E-CA21-4294-BED4-EABEBB4DC368Q59340254-021C8A94-DDEC-403F-BB03-D76A2ED06526Q88262844-F1F5A380-F2E7-4380-B432-3F45DB062840
P50
description
researcher ORCID ID = 0000-0002-3113-930X
@en
wetenschapper
@nl
name
Daniel M Halperin
@ast
Daniel M Halperin
@en
Daniel M Halperin
@es
Daniel M Halperin
@nl
type
label
Daniel M Halperin
@ast
Daniel M Halperin
@en
Daniel M Halperin
@es
Daniel M Halperin
@nl
prefLabel
Daniel M Halperin
@ast
Daniel M Halperin
@en
Daniel M Halperin
@es
Daniel M Halperin
@nl
P106
P1153
54993530400
P21
P31
P496
0000-0002-3113-930X